Please login to the form below

AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a fast-track review by the US FDA. ... AZ and Lilly are already carrying out one phase II/III placebo-controlled trial of AZD3293
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Project Manager - Medical Writing: Great salary and bebefits

Senior Account Manager: Competitive salary commensurate with experience

Business Unit Head, Medical Communications, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Client Services Director – Healthcare Advertising - London: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editorial Director – Medical Education (MedComms): Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Home based, Chief Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Manager: £40, 000 - £45, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....